Oxford BioDynamics PLC OBD signs fifth collaboration agreement
November 08 2018 - 1:01AM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
08 November 2018
08 November 2018
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics signs fifth collaboration agreement in
immuno-oncology space
-- Agreement with major US biopharmaceutical company
demonstrates value of the wide range of immuno-oncology biomarker
applications recently developed using EpiSwitch(TM)
-- High resolution mapping with the EpiSwitch(TM) technology
will be used to evaluate risks, linked to the clinical benefit of
treatment
Oxford BioDynamics Plc is pleased to announce that it has
entered into its fifth collaboration agreement for the development
of predictive biomarkers for immuno-oncology (IO) therapeutics.
IO is a fast-growing field, with a number of therapies for the
treatment of cancers, in particular immune checkpoint inhibitors,
demonstrating a highly efficacious response in certain patients.
However, many current IO treatments remain limited in their utility
due to a low response rate, and significant subsets of patients not
benefiting from a clinically meaningful response to treatment.
There is a need for robust stratification of patients in order
to accurately exclude those that will not respond to these IO
therapeutics, as well as for strong differentiation of individual
IO treatments from alternative therapeutic options. OBD has already
established its position in this field with a number of robust
biomarker-based predictive patient stratifications for several IO
assets, including both PD-1 and PD-L1 inhibitors.
In this further expansion of its technology application, Oxford
BioDynamics will use its EpiSwitch(TM) platform to offer high
resolution mapping of epigenetic profiles in patients, so that
epigenetic risks, in the context of information from other
regulatory modalities, could be linked to the clinical benefit of
treatment.
This represents the fifth collaboration agreement that Oxford
BioDynamics has entered into in the IO field. Financial terms of
the agreement are not disclosed.
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, said:
"We are pleased to have entered into this new agreement with a
major US biopharmaceutical company in the dynamic field of
immuno-oncology, as there is a high need for the identification of
epigenetic biomarkers to evaluate drug performance in therapeutic
development programmes. This agreement represents the fifth
contract we have signed in IO, continuing to validate the potential
of our EpiSwitch(TM) technology in this space."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMMGMZNVGRZZ
(END) Dow Jones Newswires
November 08, 2018 02:01 ET (07:01 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024